Relmada Therapeutics IncNASDAQ:RLMD
- LAST PRICE2.7700
- TODAY'S CHANGE (%)-0.0200 (-0.7168%)
- Bid / Lots2.7700/ 2
- Ask / Lots2.8300/ 2
- Open / Previous Close2.7700 / 2.7900
- Day Range
- 52 Week Range
- Volume5,996
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RLMD |
|---|---|---|
| 09:32 ET | 1321 | 2.7111 |
| 09:34 ET | 100 | 2.7591 |
| 09:38 ET | 900 | 2.77 |
| 09:41 ET | 130 | 2.7703 |
| 09:45 ET | 597 | 2.7788 |
| 09:50 ET | 100 | 2.77 |
Sep 21, 2023
Thinking about buying stock in TradeUP Acquisition Corp, Inventiva ADR, Relmada Therapeutics, P3 Health Partners, or Nikola Corp?, from 9:31AM ET on Thursday Sep 21, 2023 by Dow Jones
9:31AM ET on Thursday Sep 21, 2023 by Dow Jones
Sep 20, 2023
DJ Relmada Therapeutics Shares Rise 18% After Positive Trial Data for REL-1017, from 9:43AM ET on Wednesday Sep 20, 2023 by Dow Jones
9:43AM ET on Wednesday Sep 20, 2023 by Dow JonesRelmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder, from 8:30AM ET on Wednesday Sep 20, 2023 by Dow Jones
8:30AM ET on Wednesday Sep 20, 2023 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Relmada Therapeutics Inc | 84.0M | -0.6x | --- |
Kezar Life Sciences Inc | 82.9M | -1.0x | --- |
Bioatla Inc | 85.6M | -0.7x | --- |
BioXcel Therapeutics Inc | 85.2M | -0.4x | --- |
Immunome Inc | 88.3M | -3.3x | --- |
Nkarta Inc | 79.0M | -0.6x | --- |
Company Information
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), which is an N-methyl-D-aspartate (NMDA) receptor antagonist. The Company’s lead product candidate, esmethadone, is a new chemical entity (NCE) developed as a rapidly acting, oral agent for the treatment of depression, central nervous system (CNS) diseases and other potential indications. The Company’s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission and is in development for both the adjunctive and monotherapy treatment of major depressive disorder.
Contact Information
- Headquarters
- 2222 Ponce De Leon Blvd. 3Rd FloorCORAL GABLES, FL, United States 33134
- Phone
- 646-876-3459
- Fax
- ---
Executives
- Independent Chairman of the Board
- Charles Casamento
- Chief Executive Officer, Director
- Sergio Traversa
- Chief Financial Officer
- Maged Shenouda
- Chief Accounting, Compliance Officer
- Charles Ence
- Acting Chief Scientific Officer
- Paolo Manfredi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $84.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 30.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.14 |
EPS | $-4.29 |
Book Value | $4.67 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
